Source:http://linkedlifedata.com/resource/pubmed/id/15389436
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
10
|
| pubmed:dateCreated |
2004-9-24
|
| pubmed:abstractText |
We evaluated prognostic factors of melphalan/fludarabine-based dose-reduced allografts in patients with multiple myeloma. From 1998 to 2002, 120 patients with multiple myeloma were treated with melphalan/fludarabine followed by allogeneic stem cell transplantation. The cumulative risk at 1 year for treatment-related mortality (TRM) was 18% (95% confidence interval [CI], 12%-28%). In a multivariate analysis, relapse after prior high-dose chemotherapy was the most significant risk factor for TRM (hazard ratio [HR], 2.80; 95% CI, 1.16-6.74; P =.02), relapse (HR, 4.14; 95% CI, 2.04-8.38; P <.001), event-free survival (HR, 3.11; 95% CI, 1.77-5.46; P <.001), and overall survival (HR, 2.69; 95% CI, 1.35-5.35; P =.005). In addition, relapse was also significantly diminished by chronic graft-versus-host disease (GVHD) in a time-dependent Cox model (HR, 0.37; 95% CI, 0.16-0.87; P =.02). At transplantation, 8% of the patients were in complete remission, whereas 27% had progressive disease. After allografting, 49% achieved complete remission, and 38% achieved partial remission. In a subgroup of patients with chemosensitivity at transplantation and no relapse after prior high-dose chemotherapy who underwent transplantation with peripheral blood stem cells (n = 46), the cumulative risk of TRM at 1 year was only 8% (95% CI, 1%-54%). The 2-year estimated event-free and overall survival was 60% (95% CI, 42%-78%) and 75% (95% CI, 59%-91%), respectively, for related donors (n = 34) and was 81% (95% CI, 59%-100%) and 92% (95% CI, 76%-100%), respectively, for unrelated donors (n = 12).
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Oct
|
| pubmed:issn |
1083-8791
|
| pubmed:author |
pubmed-author:AlegreAdrianA,
pubmed-author:AyukFrancisF,
pubmed-author:BeyerJörgJ,
pubmed-author:BrandRonaldR,
pubmed-author:FauserAxelA,
pubmed-author:KiehlMichaelM,
pubmed-author:KlingemannHansH,
pubmed-author:KrögerNicolausN,
pubmed-author:LeonAngelA,
pubmed-author:MartinoRodrigoR,
pubmed-author:MyintHanH,
pubmed-author:NaglerArnonA,
pubmed-author:Perez-SimonJose AJA,
pubmed-author:San MiguelJesus FJF,
pubmed-author:SayerHerbert GottfriedHG,
pubmed-author:SchwerdtfegerRainerR,
pubmed-author:ShimoniAvichaiA,
pubmed-author:TomasJose FJF,
pubmed-author:ZabelinaTatjanaT,
pubmed-author:ZanderAxel RolfAR
|
| pubmed:issnType |
Print
|
| pubmed:volume |
10
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
698-708
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:15389436-Adult,
pubmed-meshheading:15389436-Aged,
pubmed-meshheading:15389436-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:15389436-Chronic Disease,
pubmed-meshheading:15389436-Female,
pubmed-meshheading:15389436-Graft Survival,
pubmed-meshheading:15389436-Graft vs Host Disease,
pubmed-meshheading:15389436-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:15389436-Humans,
pubmed-meshheading:15389436-Male,
pubmed-meshheading:15389436-Melphalan,
pubmed-meshheading:15389436-Middle Aged,
pubmed-meshheading:15389436-Multiple Myeloma,
pubmed-meshheading:15389436-Prognosis,
pubmed-meshheading:15389436-Recurrence,
pubmed-meshheading:15389436-Remission Induction,
pubmed-meshheading:15389436-Salvage Therapy,
pubmed-meshheading:15389436-Survival Analysis,
pubmed-meshheading:15389436-Transplantation, Autologous,
pubmed-meshheading:15389436-Transplantation, Homologous,
pubmed-meshheading:15389436-Treatment Outcome,
pubmed-meshheading:15389436-Vidarabine
|
| pubmed:year |
2004
|
| pubmed:articleTitle |
Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.
|
| pubmed:affiliation |
Bone Marrow Transplantation, University Hospital Hamburg, Germany. nkroeger@uke.uni-hamburg.de
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|